page_title_detailed

Triple-negative breast cancer

image_row
Mature woman bravely looking at camera
general_content

When breast cancer is described as triple-negative, this means that the cancer cells do not have certain kinds of receptors, or proteins, that help some types of breast cancer to grow.

When breast cancer cells are triple-negative, they:

  • Test negative for estrogen receptors and progesterone receptors, which confirms that these hormones are not fueling the cancer’s growth
  • Test negative for excess amounts of HER2 receptors, which means that a gene called HER2 is not helping the cancer to grow

These three negative tests mean that triple-negative breast cancer does not benefit from medicines such as tamoxifen, which treats hormone receptor-positive breast cancers, or medicines such as trastuzumab (Herceptin), which treats HER2-positive breast cancers.

Still, it’s important to know that in some cases, triple-negative breast cancers can test positive for low amounts of HER2. This is called HER2-low or HER2-ultralow breast cancer. If the cancer is metastatic (has spread to other parts of the body), trastuzumab deruxtecan (Enhertu) may be a treatment option.

Triple-negative breast cancer (TNBC) makes up about 10 to 15% of all breast cancers. It’s more common in younger women, Black women, and women with inherited BRCA1 mutations. In men, TNBC is rare, although it can happen.

Overall, triple-negative breast cancer tends to be more aggressive and more likely to recur (come back) than other types of breast cancer. For people with triple-negative breast cancer who remain free of disease 5 years after completing treatment, the risk of recurrence after that is very low. Because of the aggressive nature of TNBC, combined with the fact that TNBC is a less common type, you may benefit from extra support in navigating this diagnosis.

We invite you to:

on_this_page
general_content

What makes triple-negative breast cancer different?

Every case of breast cancer is different. But compared to other breast cancers, triple-negative breast cancer tends to be more aggressive and more difficult to treat. This is because:

  • TNBC cells are usually higher-grade. High-grade cancer cells divide and multiply more quickly than low-grade cancer cells.
  • Early-stage triple-negative breast cancer has a higher risk of recurrence (coming back after treatment) than hormone receptor-positive or HER2-positive breast cancers. However, this also can depend on stage — whether or not the cancer has moved into other areas of the breast or the lymph nodes.
  • There are fewer treatment options for triple-negative breast cancer than there are for hormone receptor-positive and HER2-positive breast cancers. Hormonal therapy and most HER2-targeted therapies aren’t effective against triple-negative breast cancer. However, ongoing research is focused on finding more effective therapies to treat triple-negative breast cancer.

Triple-negative breast cancer is treatable with surgery, chemotherapy, and radiation therapy. There are also other therapies available, including:

  • Immunotherapy: This treatment helps the body’s immune system destroy cancer cells.
  • Targeted therapies: These therapies target specific features of the cancer cells, such as a genetic mutation or too much of a certain protein.
callout
Carolyn Nickels in her chemo suite chair with a cold cap

Navigating TNBC

A project management approach

“Though a triple-negative diagnosis was not what I had hoped for, I’m a firm believer that knowledge is power, and I researched everything I could. I have experience with project management and felt the most effective way to navigate this would be to create a personal project. Projects have a beginning, an end, and some deliverables sprinkled in for good measure. Plus, they have milestones, reasons to celebrate. This approach gave me a sense of control, which helped me feel calmer.”

– Carolyn Nickels, diagnosed with TNBC in 2023

Read Carolyn's story
general_content

Signs and symptoms of triple-negative breast cancer

The symptoms of triple-negative breast cancer are the same as those that are common to most breast cancers. They can include:

  • A new lump in the breast
  • Changes in the skin: redness, dryness, flaking, or thickening of the nipple or breast skin that can sometimes be mistaken for infection
  • Nipple discharge that is not breast milk, with or without bleeding
  • A nipple that turns inward
  • Swollen lymph nodes under the arm or near the collarbone

Another type of breast cancer called inflammatory breast cancer (IBC) is often triple-negative. IBC has unique symptoms, including:

  • Breast swelling
  • A feeling of heat in the breast
  • Skin dimpling or puckering, including an orange-peel appearance

The signs of breast cancer are different than symptoms. Often, a person will experience symptoms on their own and then report them to their doctor, who may recommend tests to learn more.

Signs are identified by a doctor or radiologist during a breast exam or test, such as a mammogram or biopsy, that can help confirm a diagnosis.

general_content

How TNBC is diagnosed

All breast cancers are diagnosed in similar ways. If you notice a lump or other symptom and report it to your doctor, or if a routine screening mammogram shows a suspicious area, imaging tests may be recommended to take a closer look.

There may also be additional tests, such as removing a piece of breast tissue for examination (biopsy) and tests for specific cancer characteristics (biomarkers).

Imaging tests

Imaging tests may include:

  • Mammogram, a type of x-ray used to look for changes in the breast
  • Ultrasound, which uses high-frequency sound waves to take pictures of areas inside the body
  • MRI (magnetic resonance imaging), which uses magnets and radio waves to create 3D images of the breast

Biopsy

If imaging shows possible signs of breast cancer, your doctor will likely recommend a breast biopsy. This procedure removes a small piece of the tissue or the entire suspicious area.

Biomarker tests

After a biopsy, a doctor called a pathologist analyzes the tissue under a microscope to confirm whether or not breast cancer is present. If it is, the pathologist will perform additional tests to learn more about the features of the cancer. These are called biomarker tests.

One biomarker test, called an immunohistochemistry test (IHC test), will show whether the breast cancer cells have estrogen receptors, progesterone receptors, HER2 receptors, or all three. In some cases, IHC test results don’t clearly show whether the cancer is HER2-positive or HER2-negative. Another test called FISH (fluorescence in situ hybridization) may be needed.

Possible results are:

  • Triple-negative: The cells test negative for all three receptors.
  • Hormone receptor-positive: The cells test positive for estrogen receptors, progesterone receptors, or both.
  • HER2-positive: The cells test positive for HER2 receptors.
  • HER2-low: The cells have low levels of HER2 receptors.
  • HER2-ultralow: There are very low levels of HER2 receptors.

If you’re diagnosed with metastatic triple-negative breast cancer, which means the breast cancer has spread to other parts of the body, immunohistochemistry testing can also check the cells for a protein called PD-L1. This can determine whether immunotherapy is likely to help you.

Your doctor will share these and other test results with you in a pathology report.

Testing for metastatic breast cancer

If your doctor suspects that the cancer may have spread to other parts of the body (metastatic breast cancer), they may order additional imaging tests such as a CAT scan or PET scan.

Testing for inherited genetic mutations

Medical guidelines recommend that most people diagnosed with breast cancer receive genetic testing for inherited mutations. Testing positive for certain mutations can help you and your doctor make treatment decisions.

Presentation: Understanding today’s TNBC treatment options

In this presentation from the 2026 Living Beyond Breast Cancer Summit, Monique Gary, DO, MSc, FACS, FSSO, explains:

  • Current treatments for early-stage and metastatic triple-negative breast cancer
  • How biomarker and genetic testing helps guide treatment planning
  • Questions to ask your care team
  • Encouraging treatment research and clinical trials
general_content

Treatment

Your treatment plan is based not only on the cancer’s triple-negative status but also the cancer stage and other factors included in your pathology report after a biopsy or other breast cancer-removing surgery. These factors may include:

  • The tumor size
  • The cancer’s grade, which shows how quickly the cancer cells are dividing and how different they look from normal cells
  • Whether the cancer has traveled to lymph nodes

If the cancer is metastatic, your doctor may also recommend testing for a protein called PD-L1. PD-L1-positive triple-negative breast cancer is eligible for immunotherapy treatment.

Treating early-stage triple-negative breast cancer

Treatment for early-stage triple-negative breast cancer depends on whether the cancer is small enough to be removed with surgery, or if chemotherapy is needed first to shrink a larger tumor and/or any cancer in the lymph nodes.

 Treating smaller triple-negative breast cancers

Treatment options can include:

Treating larger triple-negative breast cancers

For larger cancers that have a higher risk of coming back (recurrence), treatments may be given first to shrink the tumor and any cancer in the lymph nodes. This is called neoadjuvant therapy. These treatments may include:

After surgery, more treatments may be given to destroy any remaining cancer cells and lower the risk of recurrence. These can include:

Your doctor can help you decide what combination of treatments makes sense for your situation and the features of the cancer.

Treating metastatic triple-negative breast cancer

For metastatic triple-negative breast cancer, first treatment options are based on:

Treatment plans may include the following medicines:

Immunotherapy

Immunotherapy helps the body’s immune system slow or stop cancer growth. Pembrolizumab is an immunotherapy approved to treat metastatic triple-negative breast cancer that tests positive for the PD-L1 protein.

Antibody-drug conjugates

Antibody-drug conjugates are medicines that pair a targeted therapy with chemotherapy to deliver chemotherapy directly to cancer cells. Three antibody-drug conjugates are available to treat metastatic triple-negative metastatic breast cancer:

PARP inhibitors

PARP inhibitors are targeted therapies that stop an enzyme called PARP from repairing cancer cell DNA. In order to receive these medicines, you must also test positive for an inherited BRCA mutation. There are two PARP inhibitors approved to treat metastatic TNBC:

Common first treatments and combinations

If the cancer tests positive for the PD-L1 protein, first treatments may include:

If the cancer tests negative for PD-L1, first treatment may include sacituzumab govitecan alone or datopotamab deruxtecan.

If the cancer tests negative for PD-L1 negative but the person has an inherited BRCA mutation, first treatment may include:

Your care team may also discuss clinical trials with you. Clinical trials are research studies that can provide access to treatments that may be more effective than currently approved medicines.

Radiation therapy

Radiation therapy may be used to treat any areas of cancer spread that are causing pain, discomfort, or other symptoms. These may affect the bones, brain, spine, or chest area.

Surgery

Surgery is not usually part of treatment for metastatic breast cancer, but it may be done in certain circumstances, such as removing a tumor that is causing pain, or helping to stabilize bones affected by bone metastasis.

More about triple-negative MBC and treatment

Visit these pages to learn more about triple-negative metastatic breast cancer and treatment options:

quote_style_1

We are entering an exciting new era in the treatment of metastatic triple-negative breast cancer, with important advances in antibody-drug conjugates, immunotherapy, and other targeted approaches. These breakthroughs, made possible through clinical trials, are expanding treatment options and offering new hope for improving both the quality and length of life for our patients.

Amy Comander, MD, FACLM

general_content

TNBC and different ethnic groups

In general, younger women and Black women have a higher chance of being diagnosed with triple-negative breast cancer than older women and women of other races or ethnicities.

In men, triple-negative breast cancer is very rare, making up less than 1% of cases.

The American Cancer Society’s Breast Cancer Facts & Figures 2024-2025 reports that:

  • In Black women, 19% of all breast cancers are triple-negative.
  • In American Indian/Alaska Native women and Hispanic women, 11% of breast cancers are triple-negative.
  • In non-Hispanic White women and Asian/Pacific Islanders, 9% of breast cancers are triple-negative.

This means Black women are about twice as likely as White women to be diagnosed with triple-negative breast cancer. Researchers are working to understand how biology may play a role in this, along with socioeconomic factors such as nutrition, chemical and environmental exposures, stress, and limited access to healthcare.

Although Black women have a higher chance of being diagnosed with triple-negative breast cancer than women of other racial and ethnic groups, the most common type of breast cancer diagnosed in Black women is hormone receptor-positive, HER2-negative cancer. It’s also the most common type of breast cancer for all other racial and ethnic groups.

callout
La-Trenda Ross side-hugging her doctor

My TNBC journey

Breast cancer, body image, and being heard

“I was bombarded with phone calls from doctors and nurses for appointments, next steps, and questions. It was overwhelming, but necessary. I had multiple consultations with breast surgeons and oncologists until I found the team that felt right. I chose a team who explained everything to me: the full prognosis, treatment plans, and what it meant to have triple-negative breast cancer. I needed to know I was in good hands. As a result, I am truly blessed with a medical team that cares.”

Read La-Trenda's story
general_content

Risk of recurrence

In early-stage TNBC, the goals of treatment are to remove all of the breast cancer and destroy any cells that have spread beyond the original tumor. These cells can move through the bloodstream and lymphatic system (lymph nodes and vessels) into other parts of the body. Treatments such as chemotherapy, immunotherapy, and targeted therapy aim to lower the risk of recurrence (cancer coming back).

Treatment for early-stage TNBC often includes neoadjuvant chemotherapy (chemotherapy given before surgery). For tumors larger than 2 centimeters that test positive for PD-L1 — with or without cancer in the lymph nodes — chemotherapy and immunotherapy are commonly recommended. For TNBC with these features, this regimen has resulted in improved outcomes.

Still, as with other types of breast cancer, the risk of early-stage TNBC coming back depends on the features of the cancer such as stage, grade, and other characteristics that are shown on your pathology report after surgery.

Early-stage triple-negative breast cancer has a higher risk of recurrence than other types of breast cancer. The risk of the cancer coming back is highest within the first 5 years after treatment.

  • About 30 to 40% of people with TNBC experience a recurrence within 5 years.
  • The recurrence rate is higher — about 50% — if a person had chemotherapy and/or immunotherapy before surgery and cancer cells were found after those treatments.

If the cancer has not returned 5 years after completing treatment, the risk then becomes much lower. Experts at M.D. Anderson Cancer Center report that recurrence risk 5 years after finishing treatment is only about 2 to 3%. So, as time goes on, your risk may be even lower than that of someone treated for hormone receptor-positive breast cancer.

After treatment, it’s important to have regular follow-up visits and screening tests as recommended by your care team.

Managing fear of recurrence

Although triple-negative breast cancer has a higher risk of recurrence, about 60% of early-stage triple-negative breast cancers have an excellent response to treatment. People in this group may not ever have a recurrence.

Still, you may feel overwhelmed by worries about breast cancer returning. Birthdays, anniversaries, and holidays can bring these emotions to the surface. So can news about a friend, family member, or a famous person’s diagnosis.

It’s very common for fear of recurrence to be stronger before you go for follow-up appointments and when you wait for test results. To feel calmer, try some of our self-care tips to manage stress and anxiety.

You may also want to consider finding emotional support through counseling, a support group, or other programs. Talking with someone who understands can help a great deal in reducing your anxiety and stress.

callout
Angel Rinker selfie with a big white floral arrangement behind her

Stepping up for support

Healing from TNBC

“Support was different when it came from other survivors [of TNBC]. Other supports helped, but not in the same ways. The people around me were helping with babysitting or fundraising, but as far as the emotional part, I still was really, really lonely.

With the support groups, it was incredibly helpful to talk to other people who were going through the same thing or who had been there. It’s still where I get a lot of my support.”

Read Angel's story
general_content

Triple-negative breast cancer and relationships

Many people don’t really understand triple-negative breast cancer. Having to explain it can feel overwhelming. If you participate in breast cancer support groups or have friends or family who’ve been diagnosed, you may spend a lot of time with people who have other types of breast cancer. Sometimes, you may feel as if your concerns aren’t fully understood.

There are other potential challenges, too. Because triple-negative breast cancer is often described as aggressive or high risk, some people may react to your diagnosis in a way that can feel upsetting. If this happens, it can be distressing — especially at a time when you are focused on getting well.

Here are some ways to respond:

  • Gently explain that there are several very effective treatment options for triple-negative breast cancer. These include chemotherapy, immunotherapy, and targeted therapies.
  • If someone continues to say things that are emotionally triggering, be direct and say, “Thank you for your concern, but you are not helping me right now.”
  • Give your family and friends concrete ways to support you. They might not know what to do or how to talk with you about your diagnosis. Ask for specific types of help, such as meal preparation, carpooling, or running errands.

Remember, you have control over who you tell and how many details you share. Consider giving more details to those who are supportive.

It can also help to stay focused on things you can do to support your whole self, such as getting good nutrition and exercise and exploring complementary therapies, including art therapy, Mindfulness-Based Stress Reduction, guided imagery, expressive writing, and yoga.

general_content

Follow-up care for triple-negative breast cancer

Your healthcare team will work with you to develop a follow-up plan. This typically includes:

  • Regular doctor visits and physical exams
  • Annual screening mammograms if mastectomy wasn’t part of your treatment
  • Imaging tests if you’re experiencing any unusual symptoms

Learn more about follow-up care for TNBC.

featured_video

Living with a history of triple-negative breast cancer

Melissa Berry and Valerie Blackwell-Howard, two women diagnosed with triple-negative breast cancer, discuss their diagnosis, life after treatment, and how they have each moved forward while living with a history of TNBC.

general_content

3 myths about triple-negative breast cancer

MYTH: People with triple-negative breast cancer can have the same treatments as all other people with breast cancer.

FACT: It’s possible you’ll get some of the same types of chemotherapy that are given for hormone receptor-positive or HER2-positive breast cancers. But triple-negative breast cancer is not treated with some of the drugs used to treat other types of breast cancers. Drugs that do not treat triple-negative breast cancer include hormonal therapies and HER2-targeted therapies.

Early-stage triple-negative breast cancer is usually treated with chemotherapy, sometimes combined with immunotherapy.

Metastatic triple-negative breast cancer is often managed with:

Some people in your life may not understand how triple-negative breast cancer is different than other breast cancers, or why treatments given to other people may not be the right for you. Having to explain this can be frustrating, especially if you are just learning about this diagnosis yourself. Connecting with others who share your experience can help. Learn more about ways to meet others who understand by visiting these pages:

MYTH: Triple-negative breast cancer is always hard to treat.

FACT: TNBC is often more aggressive than some other types of breast cancer. But there are some very effective treatments for triple-negative disease.

If you see statistics about life expectancy that worry you, or you hear your doctor or others say TNBC is hard to treat, remember that statistics generalize the experiences of large numbers of people. They don’t reflect the experience of one person, and may not describe the experience you have.

How well your treatment will work depends on many factors, including the tumor size, specific features of the cancer, and whether the cancer has traveled to the lymph nodes.

MYTH: Only Black women get triple-negative breast cancer.

FACT: Triple-negative breast cancers affect people of all races and ethnic background. Breast cancers in Black women are more likely to be triple-negative than those in White women.

related_resources_article_carousel
3_callout_columns
stay_connected

Stay connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.

Reviewed and updated: July 10, 2026

Reviewed by: Amy Comander, MD, FACLM

Tagged:

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.